IMAC Holdings, Inc. provides medical services through integrated medicine and chiropractic regeneration centers. The company is headquartered in Franklin, Tennessee and currently employs 15 full-time employees. The company went IPO on 2019-02-13. The Company, through its subsidiary, Ignite Proteomics LLC (Ignite Proteomics), leverages its multi-analyte proteomic assay to help oncologists pinpoint the effective targeted therapies for each patient. Its product is a patented Reverse Phase Protein Array (RPPA) technology platform, which can quantify protein signaling to support oncology clinical treatment decisions and biopharmaceutical drug development. Ignite Proteomics operates a CLIA-certified and CAP-accredited laboratory and offers single-gene tests by evaluating entire protein pathways in cancer cells. Its commercially available lab developed test (LDT), the Ignite RPPA Assay for Breast Cancer, is being utilized by oncologists across the United States to assist in making the targeted treatment plan for their patients with advanced breast cancer.